Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Danicamtiv in Healthy Japanese and Caucasian Participants
NCT05806359Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danicamtiv in dilated cardiomyopathy (DCM) and heart failure with reduced ejection fraction (HFrEF) (4 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants with Adverse Events (AEs), Number of Participants with Vital Sign Abnormalities and 3 more. Started Mar 2023; status: completed.
02
Drugs
danicamtiv
03
Conditions
dilated cardiomyopathy (DCM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05806359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806359.